期刊
ANZ JOURNAL OF SURGERY
卷 78, 期 11, 页码 955-967出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1445-2197.2008.04712.x
关键词
angiogenesis; anti angiogenic agents; chemotherapy; clinical trials; combretastatins; neovasculature; OXi 4503; solid organ malignancies; tumour vasculature; vascular disrupting agents
类别
Selective targeting of the tumour vasculature in the treatment of solid organ malignancies is an alternative to conventional chemotherapy treatment. As the tumour progressively increases in size, angiogenesis or the formation of new vasculature is essential to maintain the tumour's continual growth and survival. Therefore disrupting this angiogenic process or targeting the neovasculature can potentially hinder or prevent further tumour expansion. Many anti angiogenic agents have been investigated with many currently in clinical trials and exhibiting varied results. Vascular disrupting agents such as the Combretastatins and OXi 4503 have shown promising preclinical results and are currently being examined in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据